SK Group's vaccine maker — develops its own vaccines and contract-manufactures for global partners such as Novavax.
SK Group's vaccine maker — develops its own vaccines and contract-manufactures for global partners such as Novavax.
Sells vaccines mainly to governments and international buyers, and earns contract-manufacturing fees for producing others' vaccines, boosted by the COVID period and fallen back as demand normalised. Buying a majority of IDT Biologika of Germany in 2023 added European manufacturing capacity; partner Sanofi co-develops its next-generation pneumococcal vaccine.
Moat: narrow (regulatory licence, process know-how). One of few Asian vaccine makers with own R&D plus GMP fill-finish/CDMO capacity.
Headquarters: Seongnam, South Korea · Founded: 2018 · Employees: 1,129
Size SKBS (302440.KS) is a South Korea Health Care company (Biotechnology) with a market value of $2.25B, the 128th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩38,200 on 18 Nov 2026.
Performance Over six months the shares fell 11.6%, against -4.8% for the median peer and -37.2% for the South Korea market (cap-weighted) — 9th lowest of 20 in its peer set.
Growth Revenue grew 10.7% over the last twelve months (peer median +4.1%); the operating margin is -22.7% (peer median -15.4%).
Valuation It trades at 4.3× enterprise value to sales against a peer median of 9.8× (3rd cheapest of 15).
Capital Return on invested capital runs 12.2 points below its cost of capital (6.0% WACC).
Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩691B | ₩651B | ₩268B | ₩370B | ₩457B |
| Revenue growth | — | +143% | -28% | -19% | — |
| Gross profit | ₩87.3B | ₩59.5B | ₩22.1B | ₩136B | ₩236B |
| EBITDA | -₩58.2B | -₩60.3B | -₩119B | -₩8.76B | ₩88.4B |
| Net income | -₩98.6B | -₩57.4B | -₩53.9B | ₩22.3B | ₩122B |
| Free cash flow | -₩127B | -₩80.6B | -₩292B | -₩14.1B | -₩198B |
| Capital expenditure | ₩224B | ₩260B | ₩172B | ₩50.3B | ₩76.5B |
| Total debt | ₩559B | ₩470B | ₩393B | ₩20.6B | ₩113B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| SKBS 302440.KS | $2.25B | -12% | +11% | -23% | 4.3× | n/a |
| GC Biopharma 006280.KS | $1.12B | -10% | -3% | 4% | 1.2× | n/a |
| Novavax NVAX | $1.31B | -14% | -61% | -17% | 2.4× | n/a |
| Sanofi SAN.PA | $114B | +13% | +15% | 27% | 2.6× | -4.8% |
| GSK GSK.L | $97.9B | -3% | +4% | 25% | 2.8× | -0.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 302440.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.7% | -4.9% | 6th highest of 21 |
| 6-month return | -11.6% | -4.8% | 9th lowest of 20 |
| Distance from 52-week high | -32.4% | -35.4% | 10th highest of 21 |
| Revenue growth (TTM) | +10.7% | +4.1% | 8th highest of 17 |
| Operating margin | -22.7% | -15.4% | 7th lowest of 15 |
| EV / Sales | 4.3× | 9.8× | 3rd cheapest of 15 |
| ROIC minus cost of capital | -12.2 pp | -5.7 pp | 5th lowest of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| SKBS 302440.KS | South Korea | $2.25B | -12% | +11% | -23% | 4.3× | n/a | n/a |
| Vimian VIMIAN.ST | Sweden | $2.26B | +51% | +8% | 19% | 5.0× | 13.4% | +44.5% |
| Lakefront Biotherapeutics LKFT.AS | Netherlands | $2.26B | +31% | +223% | 64% | n/a | n/a | n/a |
| Arcus Biosciences RCUS | United States | $2.27B | -34% | -58% | -475% | 17.6× | n/a | n/a |
| Pharvaris PHVS | United States | $2.21B | +7% | n/a | n/a | n/a | n/a | n/a |
| Hebei Changshan Biochemical Pharmaceutical 300255.SZ | China | $2.33B | -59% | 0% | -25% | 19.4× | n/a | n/a |
| Beam Therapeutics BEAM | United States | $2.17B | -22% | +163% | -268% | 9.4× | n/a | n/a |
| Celldex Therapeutics CLDX | United States | $2.16B | -11% | -94% | -211,685% | 9,677.0× | n/a | n/a |
| Zealand Pharma A/S ZEAL.CO | Denmark | $2.16B | -30% | -50% | 46% | 0.4× | n/a | n/a |
| Palvella Therapeutics PVLA | United States | $2.14B | +27% | -100% | n/a | n/a | n/a | n/a |
| BGI Genomics 300676.SZ | China | $2.13B | -15% | 0% | -14% | 3.2× | n/a | n/a |
| Alamar Biosciences ALMR | United States | $2.12B | +51% | +195% | -42% | 26.1× | n/a | n/a |
| Evopoint Biosciences 688837.SS | China | $2.08B | n/a | n/a | n/a | 53.6× | n/a | n/a |
| Walvax Biotechnology 300142.SZ | China | $2.48B | -26% | -23% | 5% | 9.4× | 29.5% | -3.8% |
| Aurinia Pharmaceuticals AUPH | United States | $2.03B | -5% | +21% | 45% | 5.0× | 3.5% | +41.4% |
| Immunome IMNM | United States | $1.98B | -22% | -100% | n/a | n/a | n/a | n/a |
| Xiamen Amoytop Biotech 688278.SS | China | $2.56B | -27% | +18% | 27% | 4.3× | -0.6% | +36.0% |
| Xencor XNCR | United States | $2.58B | +204% | +34% | -73% | 11.7× | n/a | n/a |
| Trevi Therapeutics TRVI | United States | $1.93B | -3% | n/a | n/a | n/a | n/a | n/a |
| Maravai Lifesciences MRVI | United States | $1.92B | +101% | +11% | -17% | 10.2× | n/a | n/a |
| MBX Biosciences MBX | United States | $2.65B | +70% | n/a | n/a | n/a | n/a | n/a |